These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 15788675

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. YKL-40 is directly produced by tumor cells and is inversely linked to EGFR in glioblastomas.
    Horbinski C, Wang G, Wiley CA.
    Int J Clin Exp Pathol; 2010 Jan 01; 3(3):226-37. PubMed ID: 20224722
    [Abstract] [Full Text] [Related]

  • 5. YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas.
    Hormigo A, Gu B, Karimi S, Riedel E, Panageas KS, Edgar MA, Tanwar MK, Rao JS, Fleisher M, DeAngelis LM, Holland EC.
    Clin Cancer Res; 2006 Oct 01; 12(19):5698-704. PubMed ID: 17020973
    [Abstract] [Full Text] [Related]

  • 6. Clinical significance of ABCA2' a possible molecular marker for oligodendrogliomas.
    Soichi O, Masanori N, Hideo T, Kazunori A, Nobuya I, Jun-ichi K.
    Neurosurgery; 2007 Apr 01; 60(4):707-14; discussion 714. PubMed ID: 17415208
    [Abstract] [Full Text] [Related]

  • 7. Galectin-3 as an immunohistochemical tool to distinguish pilocytic astrocytomas from diffuse astrocytomas, and glioblastomas from anaplastic oligodendrogliomas.
    Neder L, Marie SK, Carlotti CG, Gabbai AA, Rosemberg S, Malheiros SM, Siqueira RP, Oba-Shinjo SM, Uno M, Aguiar PH, Miura F, Chammas R, Colli BO, Silva WA, Zago MA.
    Brain Pathol; 2004 Oct 01; 14(4):399-405. PubMed ID: 15605987
    [Abstract] [Full Text] [Related]

  • 8. YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma.
    Pelloski CE, Mahajan A, Maor M, Chang EL, Woo S, Gilbert M, Colman H, Yang H, Ledoux A, Blair H, Passe S, Jenkins RB, Aldape KD.
    Clin Cancer Res; 2005 May 01; 11(9):3326-34. PubMed ID: 15867231
    [Abstract] [Full Text] [Related]

  • 9. Prognostic significance of histological grading, p53 status, YKL-40 expression, and IDH1 mutations in pediatric high-grade gliomas.
    Antonelli M, Buttarelli FR, Arcella A, Nobusawa S, Donofrio V, Oghaki H, Giangaspero F.
    J Neurooncol; 2010 Sep 01; 99(2):209-15. PubMed ID: 20174854
    [Abstract] [Full Text] [Related]

  • 10. Diagnostic and prognostic value of preoperative combined GFAP, IGFBP-2, and YKL-40 plasma levels in patients with glioblastoma.
    Gállego Pérez-Larraya J, Paris S, Idbaih A, Dehais C, Laigle-Donadey F, Navarro S, Capelle L, Mokhtari K, Marie Y, Sanson M, Hoang-Xuan K, Delattre JY, Mallet A.
    Cancer; 2014 Dec 15; 120(24):3972-80. PubMed ID: 25139333
    [Abstract] [Full Text] [Related]

  • 11. Protein and mRNA levels of YKL-40 in high-grade glioma.
    Kazakova MH, Staneva DN, Koev IG, Staikov DG, Mateva N, Timonov PT, Miloshev GA, Sarafian VS.
    Folia Biol (Praha); 2014 Dec 15; 60(6):261-7. PubMed ID: 25629266
    [Abstract] [Full Text] [Related]

  • 12. Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas.
    Iwamoto FM, Hottinger AF, Karimi S, Riedel E, Dantis J, Jahdi M, Panageas KS, Lassman AB, Abrey LE, Fleisher M, DeAngelis LM, Holland EC, Hormigo A.
    Neuro Oncol; 2011 Nov 15; 13(11):1244-51. PubMed ID: 21831900
    [Abstract] [Full Text] [Related]

  • 13. Caveolin-1 expression is variably displayed in astroglial-derived tumors and absent in oligodendrogliomas: concrete premises for a new reliable diagnostic marker in gliomas.
    Cassoni P, Senetta R, Castellano I, Ortolan E, Bosco M, Magnani I, Ducati A.
    Am J Surg Pathol; 2007 May 15; 31(5):760-9. PubMed ID: 17460461
    [Abstract] [Full Text] [Related]

  • 14. Gene expression-based molecular diagnostic system for malignant gliomas is superior to histological diagnosis.
    Shirahata M, Iwao-Koizumi K, Saito S, Ueno N, Oda M, Hashimoto N, Takahashi JA, Kato K.
    Clin Cancer Res; 2007 Dec 15; 13(24):7341-56. PubMed ID: 18094416
    [Abstract] [Full Text] [Related]

  • 15. Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma.
    Tanwar MK, Gilbert MR, Holland EC.
    Cancer Res; 2002 Aug 01; 62(15):4364-8. PubMed ID: 12154041
    [Abstract] [Full Text] [Related]

  • 16. Glial fibrillary acidic protein and its fragments discriminate astrocytoma from oligodendroglioma.
    Luider TM, Kros JM, Sillevis Smitt PA, van den Bent MJ, Vecht CJ.
    Electrophoresis; 1999 Aug 01; 20(4-5):1087-91. PubMed ID: 10344289
    [Abstract] [Full Text] [Related]

  • 17. Quantitative proteomic analysis shows differentially expressed HSPB1 in glioblastoma as a discriminating short from long survival factor and NOVA1 as a differentiation factor between low-grade astrocytoma and oligodendroglioma.
    Gimenez M, Marie SK, Oba-Shinjo S, Uno M, Izumi C, Oliveira JB, Rosa JC.
    BMC Cancer; 2015 Jun 25; 15():481. PubMed ID: 26108672
    [Abstract] [Full Text] [Related]

  • 18. Clarifying the diffuse gliomas: an update on the morphologic features and markers that discriminate oligodendroglioma from astrocytoma.
    Gupta M, Djalilvand A, Brat DJ.
    Am J Clin Pathol; 2005 Nov 25; 124(5):755-68. PubMed ID: 16203285
    [Abstract] [Full Text] [Related]

  • 19. Association between YKL-40 and adult primary astrocytoma.
    Zhang W, Kawanishi M, Miyake K, Kagawa M, Kawai N, Murao K, Nishiyama A, Fei Z, Zhang X, Tamiya T.
    Cancer; 2010 Jun 01; 116(11):2688-97. PubMed ID: 20499402
    [Abstract] [Full Text] [Related]

  • 20. Prognostic implications of immunohistochemically detected YKL-40 expression in breast cancer.
    Kim SH, Das K, Noreen S, Coffman F, Hameed M.
    World J Surg Oncol; 2007 Feb 07; 5():17. PubMed ID: 17286869
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.